Euretina Congress
Euretina Congress
October 02, 2013
1 min read

Anti-VEGF as therapy for ROP leads to less myopia, astigmatism

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

HAMBURG — Anti-VEGF injection might be a valid alternative to laser photocoagulation in retinopathy of prematurity, leading to significantly lower refractive error, according to studies presented at the Euretina meeting.

“We started using bevacizumab 3 to 4 years ago, in a lower, 0.4mg dose compared to other studies,” Jost Jonas, MD, said. 

Jost Jonas, MD

Jost Jonas

Following a first study on 23 eyes of 12 infants, where complete regression of the retinal neovascularization was observed within 2 to 3 weeks, another study with a follow-up of 1 year was performed to measure the development of refractive error in the group of bevacizumab-treated infants compared with a group of 26 eyes of 13 children treated with laser photocoagulation. Gestational age was 25 weeks in both groups, birth weight was 622 g and 617 g respectively.

Myopia at the end of the follow-up was found to be much lower in the bevacizumab group with a mean of  -1D compared to the -4.4D of the laser group.  Astigmatism was 1D vs. 1.82D.

“The presence of moderate and high myopia was significantly lower in the bevacizumab group,” Jonas said.

A similar study with extended follow-up to two years had comparable results. 

The better effect on refraction adds up to other advantages of anti-VEGF over laser treatment. However, Jonas said, “no information on the long-term effects on growth or on any other potential systemic side effect is available at present.”

Disclosure: Jonas has no relevant financial disclosures.